EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAS pathways in prostate cancer - mediators of hormone resistance?



RAS pathways in prostate cancer - mediators of hormone resistance?



Current Cancer Drug Targets 10(8): 834-839



Although not frequently mutated in prostate cancer Ras isoforms play a pivotal role in multiple pathways that have been implicated in prostate cancer progression to androgen independence. These have included growth factor and cytokine induced activation of the androgen receptor and its coregulators by post translational modification. Current evidence suggests that Ras is also required for androgen receptor activation in hormone sensitive cells. More recently Ras has been shown to work synergistically with other pathways to promote prostate tumorigenesis. We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer.

(PDF emailed within 1 workday: $29.90)

Accession: 055333404

Download citation: RISBibTeXText

PMID: 20718703



Related references

New insights into the cellular pathways of hormone resistance in prostate cancer. International Journal of Molecular Medicine 6(Supplement 1): S42, 2000

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prevention Research 4(12): 2044-2050, 2012

Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncology Reports 15(6): 1453-1460, 2006

Steroid hormone synthetic pathways in prostate cancer. Translational Andrology and Urology 2(3): 212-227, 2013

The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hellenic Journal of Nuclear Medicine 12(3): 234-237, 2010

Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. Journal of Urology 168(1): 193-193, 2002

Comparison of hip extensor muscle activity including the adductor magnus during three prone hip extension exercises. PhysioTherapy Theory and Practice: 1-6, 2018

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 44(2): 172-180, July 1, 2000

Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Current Cancer Drug Targets 10(4): 392-401, 2010

Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer 18(4): R103-R123, 2011

Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer. Cancer 120(2): 294-301, 2014

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. Bju International 95(9): 1327-1335, 2005

Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. Bju International 104(9): 1304-1304, 2009

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer. Cancer 121(16): 2821-2830, 2015